June will be a significant month for Biomarin on several accounts.
Firstly, the firm will soon find out whether the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) can recommend the drug vosoritide for treating achondroplasia, and secondly, the company plans to resubmit an application for approval for the gene therapy valoctocogene roxaparvovec against hemophilia A. Last year, the EMA rejected this application.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.